Let's put all the bashing and insults aside and just look at the numbers based on Vivus last conference call. They have a very expensive REMS process to fund without a partner. This will burn their cash very quickly. Until they show the finacial community clarity on how Qsymia will generate the revenue required, or they announce a partner (nothing on the horizon there), this will be a very risky investment. Expect a secondary next quarter if they can even pull one off.
Yes, let's look the numbers, 3000 physicians now prescribing Qsymia, 300 million in cash and cash eq. $17 million of the 40 million spent in Q3 was for inventory. Don't expect a secondary anytime soon. Partnership may come at anytime if the price is right for VVUS. Modified REMs in a few months. Direct advertising can start in July 2013.